HIVACAT, a development project for HIV vaccine

HIVACAT, a development project for HIV vaccine

How will an HIV vaccine act to stimulate the immune system? Which are the substances that it will contain? Currently, thousands of researchers throughout the world are researching to develop a vaccine that is able to prevent HIV infection in healthy people and, in turn, act in infected individuals by impeding the development of infection. IrsiCaixa, in collaboration with Hospital Clinic Barcelona, is currently leading the development project for a HIV vaccine called HIVACAT, an international benchmark initiated by an unprecedented public-private consortium that includes Esteve, ”la Caixa” Foundation and the Departments of Health and Innovation, Universities and Enterprise of the Catalan Government.

If the interactive does not works properly please download flashplayer


Post new comment

The content of this field is kept private and will not be shown publicly.
Enter the characters shown in the image.